spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  bazedoxifene 

 HSMN NewsFeed - 17 Dec 2013
Azure Biotech Announces Hiring of Ralph Makar as CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Oct 2013
Pfizer Inc. Announces FDA Approval of DUAVEE(TM) (conjugated estrogens/ bazedoxifene) for the Treatment of Moderate-to-Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause and the Prevention of Postmenopausal Osteoporosis [1]
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Oct 2011
Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn(R)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 15 Sep 2009
Wyeth Presents Data from Five-Year Vertebral Fracture Prevention Study with Bazedoxifene
Biopharmaceuticals
 HSMN NewsFeed - 27 Apr 2009
Ligand Announces Approval in Europe of CONBRIZA for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Sep 2008
Ligand Pharmaceuticals and the SALK Institute Enter Settlement Agreement and Mutual Release of All Claims
Biopharmaceuticals Litigation
 HSMN NewsFeed - 23 May 2008
Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Dec 2007
Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Oct 2007
Ligand Earns Milestone Payment as Wyeth Submits European Market Authorization for Bazedoxifene
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Sep 2007
Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 24 Apr 2007
Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Jun 2006
Wyeth Submits Two New Drug Applications for Women's Health Therapies
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
bazedoxifene
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.